Avid Bioservices Inc (CDMO)

[cjgaddy]

“Anti-PS, ASCO’09, and Glenn Dranoff” - Anti-PS blog, 5-8-09…
http://anti-ps.blogspot.com
http://anti-ps.blogspot.com/2009/05/anti-ps-asco-and-glenn-dranoff-interim.html

Interim data from a phase II clinical trial evaluating anti-PS in advanced breast cancer patients is slated for an oral presentation at the annual ASCO conference this year, (abstract #3005 [6-1-09 10:30am]).

Of note, immediately following the anti-PS presentation, the discussion of the three preceding presentations, (abstracts 3003-3005), is led by none other than Dr. Glenn Dranoff himself, well-known and well-published Harvard immunologist, who recently has been studying the therapeutic anti-tumor effects achieved by blocking PS-mediated signaling.

Dranoff's 2008 paper published in the journal Clinical Cancer Research, titled ”Capitalizing on the Immunogenicity of Dying Tumor Cells”, should be "required reading" for anyone interested in how exposed PS is exploited by tumors to elude the cells of the immune system. In the paper, he speaks very broadly about the role of exposed PS in the apoptotic process common to all multicellular organisms, and he outlines experiments in which autologous tumor cells combined with PS-blocking yielded some very impressive experimental anti-tumor results.
3-15-08 CCR: http://clincancerres.aacrjournals.org/cgi/content/full/14/6/1603

Also worth reading is Dranoff's recent WIPO patent application, in which he discusses tumor vaccines utilizing autologous tumor cells altered to express GM-CSF, combined with PS signaling blockers - including anti-PS antibodies.
http://tinyurl.com/qhtk9r

= = = = = = = =
Dr. Glenn Dranoff profile: http://tinyurl.com/rbfar6
…Associate Professor of Medicine, Harvard Medical School

= = = = = = = = = = = = =
ASCO 2009 PROGRAM BY-DAY (231-pg PDF): http://tinyurl.com/cn9qlc

MON. 6-1-09 9am-12pm, Abstract #3005 (pg.248)
[updated prelim. data from the ongoing Ph.2 Bavi+Doce/MBC/GA. trial]…
ORAL ABSTRACT SESSION
Track: Developmental Therapeutics: Immunotherapy
10:30am: “Phase II Study of Bavituximab + Docetaxel in Patients with Locally Advanced or Metastatic Breast Cancer”
D. Tabagari [PI, GA. Ph.2 Trial], G. Nemsadze, M. Jincharadze, M. Janjalia, J. S. Shan [PPHM VP/Clin.Affairs]
- - - - - - - -
***Note: Immediately the Bavi Oral, “10:45am Discussion on Abstracts 3003-3005”, led by Dr. Glenn Dranoff, MD, Dana-Farber Cancer Institute, “Cancer Vaccines”
- - - - - - - -
2-12-08 PR (Ph.2 Bavi+Doce/Breast GA: 1st-Dosage): "Bavituximab represents a novel strategy for the treatment of cancer that has demonstrated encouraging potential in initial clinical studies," said David Tabagari, M.D., Ph.D., the head of Medulla Immunotherapy & Chemotherapy Clinic and P.I. of the bavituximab breast cancer trial being conducted in the Republic of Georgia. "We are pleased to have the opportunity to conduct the 1st Phase II trial of this potentially valuable new approach to treating cancer." http://tinyurl.com/36c28s

MON. 6-1-09 1-5pm, Abstract #1080 (pg.268)
[updated prelim. data from the ongoing U.S. Ph.1 Bavi-Mono Solid-Tumors trial]…
GENERAL POSTER SESSION
Track: Breast Cancer - Metastatic
“Phase I Study of Bavituximab, a Novel Anti-Phosphatidylserine Monoclonal Antibody in Patients with Advanced Refractory Cancer: Preliminary Results”
N. K. Ibrahim [MDA], L. Wong, L. Rosen, J. Shan [PPHM VP/Clin.Affairs]
• N.K. Ibrahim/PI: MDA, Breast Cancer Specialist http://tinyurl.com/clpu25
• Lucas Wong/PI: Scott&White, Co-Dir./Gastro-Int. Oncology http://tinyurl.com/dfr44x
• Lee Rosen/PI: Premier Oncology, Hematology & Oncology http://tinyurl.com/p77uu
• Joe Shan, VP/Reg&Clinical-Affairs, PPHM http://tinyurl.com/2r5h6u

ASCO Home: http://www.asco.org

3-12-09, S.King/J.Shan comments on ASCO’09: http://tinyurl.com/crl27y
On ASCO’s view of PRELIM-DATA & significance of ORAL-PRES: http://tinyurl.com/r6sdpt & http://tinyurl.com/oodcg7

History of ALL Bavi Mono & Combo Cancer Trials – see iBox at this link:
http://investorshub.advfn.com/boards/board.aspx?board_id=2076